Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1424
{ "count": 24565, "next": "http://api.gregory-ms.com/articles/?format=api&page=1425", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1423", "results": [ { "article_id": 380749, "title": "Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Drug-induced liver injury (DILI) has been observed in patients with multiple sclerosis (MS), raising concerns on the liver safety of MS drugs. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To describe DILI events with MS drugs by analyzing the FDA Adverse Event Reporting System. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> DILI reports were extracted and classified in overall liver injury (OLI), including asymptomatic elevation of liver enzymes, and severe liver injury (SLI). We performed disproportionality analysis by calculating adjusted reporting odds ratios (RORs) with 95% confidence interval (CI) and case-by-case evaluation for concomitant drugs with hepatotoxic potential. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Fampridine showed statistically significant ROR for both OLI and SLI, whereas teriflunomide and fingolimod generated solid disproportionality (ROR > 2) only for OLI (ROR, 2.31; 95% CI, 2.12–2.52; and 2.53; 2.40–2.66, respectively). Among monoclonal antibodies, only alemtuzumab generated higher-than-expected ROR for OLI (1.34; 1.09–1.65). We also detected the expected hepatotoxic potential of beta interferon and mitoxantrone. Concomitant reporting of hepatotoxic drugs ranged from 26% (dimethyl fumarate) to 90% (mitoxantrone). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> These real-world pharmacovigilance findings suggest that DILI might be a common feature of MS drugs and call for (1) formal population-based study to verify the risk of fampridine and (2) awareness by clinicians, who should assess the possible responsibility of MS drugs when they diagnose DILI. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518799598", "published_date": "2018-09-19T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 225005, "given_name": "Ippazio Cosimo", "family_name": "Antonazzo", "ORCID": "http://orcid.org/0000-0001-8046-4574", "country": null }, { "author_id": 266308, "given_name": "Elisabetta", "family_name": "Poluzzi", "ORCID": null, "country": null }, { "author_id": 283617, "given_name": "Emanuele", "family_name": "Forcesi", "ORCID": null, "country": null }, { "author_id": 184117, "given_name": "Trond", "family_name": "Riise", "ORCID": "http://orcid.org/0000-0001-9644-5140", "country": "NO" }, { "author_id": 163716, "given_name": "Kjetil", "family_name": "Bjornevik", "ORCID": "http://orcid.org/0000-0002-2892-6986", "country": "NO" }, { "author_id": 221192, "given_name": "Elisa", "family_name": "Baldin", "ORCID": "http://orcid.org/0000-0002-3277-5623", "country": "IT" }, { "author_id": 184047, "given_name": "Luigi", "family_name": "Muratori", "ORCID": "http://orcid.org/0000-0002-8748-8031", "country": null }, { "author_id": 283618, "given_name": "Fabrizio", "family_name": "De Ponti", "ORCID": null, "country": null }, { "author_id": 184049, "given_name": "Emanuel", "family_name": "Raschi", "ORCID": "http://orcid.org/0000-0003-0487-7996", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Liver injury", "drugs", "multiple sclerosis", "A contemporary analysis", "the FDA Adverse Event Reporting System" ], "doi": "10.1177/1352458518799598", "access": "restricted", "takeaways": " Drug-induced liver injury (DILI) has been observed in patients with multiple sclerosis . Fampridine showed statistically significant ROR for both OLI and SLI, whereas teriflunomide and fingolimod generated solid disproportionality (ROR > 2) only for OLI . Concomitant reporting of hepatotoxic drugs ranged from 26% (dimethyl fumarate) to 90% (mitoxantrone)", "categories": [] }, { "article_id": 381270, "title": "Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Microglia-mediated proteolysis of the triggering receptor expressed on myeloid cells-2 (TREM-2) produces soluble TREM-2 (sTREM-2) that can be measured in cerebrospinal fluid (CSF) samples. Loss-of-function mutations in TREM2 or in the gene encoding its adaptor protein cause the rare Nasu–Hakola disease (NHD). Multiple sclerosis (MS) is an autoimmune disease that in common with NHD is characterized by demyelination and microglial activation. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate the potential utility of sTREM-2 as a biomarker for MS and to follow treatment effects. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> sTREM-2 was analyzed in CSF samples from subjects with MS ( N = 59); relapsing-remitting MS (RRMS) ( N = 36), secondary progressive MS (SPMS) ( N = 20) and primary progressive MS (PPMS) ( N = 3), and controls ( N = 27). CSF levels of sTREM-2 were also assessed before and after treatment of patients with natalizumab or mitoxantrone. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> CSF levels of sTREM-2 were significantly increased in patients with RRMS, SPMS, and PPMS compared with controls. After natalizumab treatment, the levels of sTREM-2 were normalized to control levels. The levels of sTREM-2 were also reduced after mitoxantrone treatment. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Increased CSF levels of sTREM-2, a new marker of microglial activation, in MS and normalization upon treatment with either natalizumab or mitoxantrone support a role for microglial activation in active MS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458515624558", "published_date": "2016-07-11T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 244748, "given_name": "Annika", "family_name": "Öhrfelt", "ORCID": null, "country": null }, { "author_id": 205803, "given_name": "Markus", "family_name": "Axelsson", "ORCID": "http://orcid.org/0000-0003-2036-4007", "country": null }, { "author_id": 232117, "given_name": "Clas", "family_name": "Malmeström", "ORCID": "http://orcid.org/0000-0003-2477-0088", "country": "SE" }, { "author_id": 176237, "given_name": "Lenka", "family_name": "Novakova", "ORCID": "http://orcid.org/0000-0001-7899-6395", "country": "SE" }, { "author_id": 244750, "given_name": "Amanda", "family_name": "Heslegrave", "ORCID": null, "country": null }, { "author_id": 173692, "given_name": "Jan", "family_name": "Lycke", "ORCID": "http://orcid.org/0000-0002-7891-8466", "country": null }, { "author_id": 150775, "given_name": "Henrik", "family_name": "Zetterberg", "ORCID": "http://orcid.org/0000-0003-3930-4354", "country": null }, { "author_id": 332494, "given_name": "Kaj", "family_name": "Blennow", "ORCID": "http://orcid.org/0000-0002-1890-4193", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Soluble TREM-2", "cerebrospinal fluid", "patients", "multiple sclerosis", "natalizumab", "mitoxantrone" ], "doi": "10.1177/1352458515624558", "access": "open", "takeaways": " Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination and microglial activation . Loss-of-function mutations in TREM2 or in the gene encoding its adaptor protein cause the rare Nasu–Hakola disease . CSF levels of sTREM-2 significantly increased in patients with MS, SPMS, and PPMS compared with controls .", "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 299 }, { "category_id": 19, "category_description": "Novantrone, mitoxantrone", "category_name": "Novantrone", "category_slug": "novantrone", "category_terms": [ "Novantrone", "mitoxantrone" ], "article_count": 26 } ] }, { "article_id": 381943, "title": "Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Damage to venules in multiple sclerosis was first described decades ago. Today, ultrahigh magnetic field strength T2*-weighted magnetic resonance imaging (MRI) techniques depict very small cerebral veins in vivo with great anatomical detail. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> We aimed to investigate alterations of periventricular small blood vessel appearance in relation to T2 lesion count and distribution in multiple sclerosis and clinically isolated syndrome in comparison with healthy control subjects at 7 Tesla MRI. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We investigated 38 patients (including 16 with early multiple sclerosis and seven with clinically isolated syndrome) and 22 matched healthy controls at 7 Tesla. The protocol included T2*-weighted Fast Low Angle Shot, and T2-weighted Turbo Inversion Recovery Magnitude sequences. We quantified periventricular venous density by a novel region-of-interest-based algorithm, expressing the ratio of ‘veins per region-of-interest’ as well as of ‘periventricular vascular area’. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Our study revealed significantly decreased venous density in multiple sclerosis patients compared with healthy controls. Venous alterations were already detectable in clinically isolated syndrome and early multiple sclerosis, although to a smaller extent. Venous density correlated inversely with periventricular and whole-brain T2 lesion count. Furthermore, we found no indication for cerebral venous congestion in multiple sclerosis. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> High spatially resolving anatomical T2*-weighted MRI revealed vascular alterations in early stages of multiple sclerosis, presumably as a part of widespread haemodynamic and metabolic alterations. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512461391", "published_date": "2012-06-26T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 254552, "given_name": "Tim", "family_name": "Sinnecker", "ORCID": null, "country": null }, { "author_id": 261925, "given_name": "Ivan", "family_name": "Bozin", "ORCID": null, "country": null }, { "author_id": 237104, "given_name": "Jan", "family_name": "Dörr", "ORCID": null, "country": null }, { "author_id": 274831, "given_name": "Caspar F", "family_name": "Pfueller", "ORCID": null, "country": null }, { "author_id": 261927, "given_name": "Lutz", "family_name": "Harms", "ORCID": null, "country": null }, { "author_id": 243301, "given_name": "Thoralf", "family_name": "Niendorf", "ORCID": null, "country": null }, { "author_id": 255539, "given_name": "Alexander U", "family_name": "Brandt", "ORCID": null, "country": null }, { "author_id": 237109, "given_name": "Friedemann", "family_name": "Paul", "ORCID": "https://orcid.org/0000-0002-6378-0070", "country": "DE" }, { "author_id": 237092, "given_name": "Jens", "family_name": "Wuerfel", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Periventricular venous density", "multiple sclerosis", "T2 lesion count" ], "doi": "10.1177/1352458512451941", "access": "restricted", "takeaways": " Damage to venules in multiple sclerosis was first described decades ago . Today, ultrahigh magnetic field strength T2*-weighted magnetic resonance imaging (MRI) techniques depict very small cerebral veins in vivo with great anatomical detail . Venous alterations were already detectable in clinically isolated syndrome and early multiple sclerosis .", "categories": [] }, { "article_id": 381015, "title": "Remote assessment of verbal memory in MS patients using the California Verbal Learning Test", "summary": "<jats:p> We used the California Verbal Learning Test, Second Edition (CVLT-II), one component of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), to determine feasibility of a remote assessment protocol. We compared telephone-administered CVLT-II data from MS patients to data acquired in person from an independent sample of patients and healthy controls. Mixed factor analyses of variance (ANOVAs) showed no significant differences between patient groups, but between-group effects comparing patients and healthy controls were significant. In this study, CVLT-II assessment by conventional in-person and remote telephone assessment yielded indistinguishable results. The findings indicate that telephone-administered CVLT-II is feasible. Further validation studies are underway. </jats:p>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517694087", "published_date": "2017-02-01T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 247715, "given_name": "Lisa F", "family_name": "Barcellos", "ORCID": null, "country": null }, { "author_id": 263473, "given_name": "Kalliope H", "family_name": "Bellesis", "ORCID": null, "country": null }, { "author_id": 263474, "given_name": "Ling", "family_name": "Shen", "ORCID": null, "country": null }, { "author_id": 248065, "given_name": "Xiaorong", "family_name": "Shao", "ORCID": null, "country": null }, { "author_id": 263475, "given_name": "Terrence", "family_name": "Chinn", "ORCID": null, "country": null }, { "author_id": 263476, "given_name": "Seth", "family_name": "Frndak", "ORCID": null, "country": null }, { "author_id": 251282, "given_name": "Allison", "family_name": "Drake", "ORCID": null, "country": null }, { "author_id": 263477, "given_name": "Nandini", "family_name": "Bakshi", "ORCID": null, "country": null }, { "author_id": 263478, "given_name": "Jackie", "family_name": "Marcus", "ORCID": null, "country": null }, { "author_id": 263479, "given_name": "Catherine", "family_name": "Schaefer", "ORCID": null, "country": null }, { "author_id": 237074, "given_name": "Ralph HB", "family_name": "Benedict", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Remote assessment", "verbal memory", "MS patients", "the California Verbal Learning Test" ], "doi": "10.1177/1352458517694087", "access": "open", "takeaways": " We used the California Verbal Learning Test, Second Edition (CVLT-II), one component of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) to determine feasibility of a remote assessment protocol . We compared telephone-administ", "categories": [] }, { "article_id": 381948, "title": "Cortico-muscular coherence as an index of fatigue in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Highly common in multiple sclerosis (MS), fatigue severely impacts patients’ daily lives. Previous findings of altered connectivity patterns led to the hypothesis that the distortion of functional connections within the brain-muscle circuit plays a crucial pathogenic role. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> The objective of this paper is to identify markers sensitive to fatigue in multiple sclerosis. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Structural (magnetic resonance imaging with assessment of thalamic volume and cortical thickness of the primary sensorimotor areas) and functional (cortico-muscular coherence (CMC) from simultaneous electroencephalo- and surface electromyographic recordings during a weak handgrip task) measures were used on 20 mildly disabled MS patients (relapsing–remitting course, Expanded Disability Status Scale score ≤ 2) who were recruited in two fatigue-dependent groups according to the Modified Fatigue Index Scale (MFIS) score. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The two groups were similar in terms of demographic, clinical and imaging features, as well as task execution accuracy and weariness. In the absence of any fatigue-dependent brain and muscular oscillatory activity alterations, CMC worked at higher frequencies as fatigue increased, explaining 67% of MFIS variance ( p=.002). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Brain-muscle functional connectivity emerged as a sensitive marker of phenomena related to the origin of MS fatigue, impacting central-peripheral communication well before the appearance of any impairment in the communicating nodes. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512461391", "published_date": "2012-07-03T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 303803, "given_name": "L", "family_name": "Tomasevic", "ORCID": null, "country": null }, { "author_id": 303804, "given_name": "G", "family_name": "Zito", "ORCID": null, "country": null }, { "author_id": 273453, "given_name": "P", "family_name": "Pasqualetti", "ORCID": null, "country": null }, { "author_id": 303805, "given_name": "MM", "family_name": "Filippi", "ORCID": null, "country": null }, { "author_id": 303806, "given_name": "D", "family_name": "Landi", "ORCID": null, "country": null }, { "author_id": 303807, "given_name": "A", "family_name": "Ghazaryan", "ORCID": null, "country": null }, { "author_id": 303808, "given_name": "D", "family_name": "Lupoi", "ORCID": null, "country": null }, { "author_id": 303809, "given_name": "C", "family_name": "Porcaro", "ORCID": null, "country": null }, { "author_id": 265794, "given_name": "F", "family_name": "Bagnato", "ORCID": null, "country": null }, { "author_id": 303810, "given_name": "PM", "family_name": "Rossini", "ORCID": null, "country": null }, { "author_id": 303811, "given_name": "F", "family_name": "Tecchio", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Cortico-muscular coherence", "an index", "fatigue", "multiple sclerosis" ], "doi": "10.1177/1352458512452921", "access": "restricted", "takeaways": " The distortion of functional connections within the brain-muscle circuit plays a crucial pathogenic role in MS . The objective of this paper is to identify markers sensitive to fatigue in multiple sclerosis . In the absence of any fatigue-dependent brain and muscular oscillatory activity alterations, CMC worked at higher frequencies as fatigue increased, explaining 67% of MFIS variance .", "categories": [] }, { "article_id": 381769, "title": "A novel method for calculating prevalence of multiple sclerosis in Australia", "summary": "<jats:sec><jats:title>Objectives:</jats:title><jats:p> The purpose of this study was to determine the prevalence of multiple sclerosis (MS) in Australia in 2010 using a novel method based on Australia-wide prescription data for MS-specific disease modifying agents. The results obtained were validated against two other prevalence estimates. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We obtained the total number of scripts for medications that were used exclusively for the treatment of MS written in Australia for the period January–December 2010. The percentage of MS patients using medications (42–55%) was taken from state-specific surveys of MS Society clients. To estimate prevalence we divided the annual number of scripts dispensed by 12 and adjusted for penetration of medications by state. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The prevalence of MS in Australia in 2010 calculated using the prescription method was 21,283 people (95.5/100,000). This compared to 21,200 people (95.2/100,000) obtained from the Australian Bureau of Statistics (ABS) Survey of Disability, Ageing and Carers (SDAC) survey of 2009 and 20,471 people (91.9/100,000) using MS Society client numbers. Prevalence increased with increasing latitude, with the prevalence for Tasmania over seven times that of the Northern Territory. Results were sensitive to the percentage of people with MS being treated. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Calculation of prevalence of MS using nation-wide prescription data is a novel method that generates results similar to other potentially more resource-intensive methods. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-04-15T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 246576, "given_name": "Andrew J", "family_name": "Palmer", "ORCID": null, "country": null }, { "author_id": 246578, "given_name": "Peta L", "family_name": "Hitchens", "ORCID": null, "country": null }, { "author_id": 245129, "given_name": "Steve", "family_name": "Simpson", "ORCID": null, "country": null }, { "author_id": 246581, "given_name": "Beth", "family_name": "O’Leary", "ORCID": null, "country": null }, { "author_id": 246583, "given_name": "Sam", "family_name": "Colman", "ORCID": null, "country": null }, { "author_id": 177179, "given_name": "Bruce V.", "family_name": "Taylor", "ORCID": "http://orcid.org/0000-0003-2807-0070", "country": "AU" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "A novel method", "prevalence", "multiple sclerosis", "Australia" ], "doi": "10.1177/1352458513479841", "access": "restricted", "takeaways": " The prevalence of MS in Australia in 2010 calculated using the prescription method was 21,283 people (95.5/100,000) compared to 21,200 people using MS Society client numbers . Prevalence increased with increasing latitude, with the prevalence for Tasmania over seven times that of the Northern Territory .", "categories": [] }, { "article_id": 381949, "title": "Glutamate gene polymorphisms predict brain volumes in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Several genetic markers have been associated with multiple sclerosis (MS) susceptibility; however, uncovering the genetic aetiology of the complex phenotypic expression of MS has been more difficult so far. The most common approach in imaging genetics is based on mass-univariate linear modelling (MULM), which faces several limitations. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> Here we apply a novel multivariate statistical model, sparse reduced-rank regression (sRRR), to identify possible associations of glutamate related single nucleotide polymorphisms (SNPs) and multiple MRI-derived phenotypes in MS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Seven phenotypes related to brain and lesion volumes for a total number of 326 relapsing–remitting and secondary-progressive MS patients and a total of 3809 glutamate related and control SNPs were analysed with sRRR, which resulted in a ranking of SNPs in decreasing order of importance (‘selection probability’). Lasso regression and MULM were used as comparative statistical techniques to assess consistency of the most important associations over different statistical models. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Five SNPs within the NMDA-receptor-2A-subunit (GRIN2A) domain were identified by sRRR in association with normalized brain volume (NBV), normalized grey matter volume and normalized white matter volume (NMWM). The association between GRIN2A and both NBV and NWMV was confirmed in MULM and Lasso analysis. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Using a novel, multivariate regression model confirmed by two other statistical approaches we show associations between GRIN2A SNPs and phenotypic variation in NBV and NWMV in this first exploratory study. Replications in independent datasets are now necessary to validate these findings. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512461391", "published_date": "2012-07-31T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 151929, "given_name": "Eva MM", "family_name": "Strijbis", "ORCID": "http://orcid.org/0000-0001-6705-5864", "country": null }, { "author_id": 302609, "given_name": "Becky", "family_name": "Inkster", "ORCID": null, "country": null }, { "author_id": 302610, "given_name": "Maria", "family_name": "Vounou", "ORCID": null, "country": null }, { "author_id": 167454, "given_name": "Yvonne", "family_name": "Naegelin", "ORCID": "http://orcid.org/0000-0002-1315-4100", "country": null }, { "author_id": 147953, "given_name": "Ludwig", "family_name": "Kappos", "ORCID": "http://orcid.org/0000-0003-4175-5509", "country": null }, { "author_id": 243792, "given_name": "Ernst-Wilhelm", "family_name": "Radue", "ORCID": null, "country": null }, { "author_id": 243484, "given_name": "Paul M", "family_name": "Matthews", "ORCID": null, "country": null }, { "author_id": 244952, "given_name": "Bernard MJ", "family_name": "Uitdehaag", "ORCID": null, "country": null }, { "author_id": 143261, "given_name": "Frederik", "family_name": "Barkhof", "ORCID": "http://orcid.org/0000-0003-3543-3706", "country": null }, { "author_id": 243479, "given_name": "Chris H", "family_name": "Polman", "ORCID": null, "country": null }, { "author_id": 302611, "given_name": "Giovanni", "family_name": "Montana", "ORCID": null, "country": null }, { "author_id": 243288, "given_name": "Jeroen JG", "family_name": "Geurts", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Glutamate gene polymorphisms", "brain volumes", "multiple sclerosis" ], "doi": "10.1177/1352458512454345", "access": "restricted", "takeaways": " Several genetic markers have been associated with multiple sclerosis susceptibility . But uncovering the genetic aetiology of the complex phenotypic expression of MS has been more difficult so far . Here we apply a novel multivariate statistical model to identify possible associations of glutamate related single nucleotide polymorphisms (SNPs) and multiple MRI-derived phenotypes in MS .", "categories": [] }, { "article_id": 381201, "title": "Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Alterations of intestinal permeability (IP) may contribute to the pathophysiology of immune-mediated diseases. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> We investigated the possible association between IP changes and multiple sclerosis (MS). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We studied 22 patients with relapsing–remitting multiple sclerosis (RRMS) and 18 age- and sex-matched healthy donors (HDs), including five twin pairs (one concordant, and four discordant for disease). Measurement of lactulose (L) and mannitol (M; two non-metabolized sugars) levels in urine samples, after an oral load, allowed to quantify gut dysfunction. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The proportion of participants with increased IP was significantly higher in patients than in HDs (16/22 (73%) versus 5/18 (28%); p = 0.001). Accordingly, the L/M urinary ratio showed significantly higher values in patients than in controls ( p = 0.0284). Urinary mannitol concentration was significantly lower in patients than in controls ( p = 0.022), suggesting a deficit of absorption from intestinal lumen. Such changes did not appear related to patients’ clinical–radiological features. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> The relatively high proportion of IP changes in RR-MS patients seems to confirm our work hypothesis and warrants more work to confirm the result on a larger sample, and to understand the implications for related immunological disturbances and intestinal microbiota alterations. Our finding may also have relevance for oral treatments, recently introduced in clinical practice. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458516652498", "published_date": "2016-07-11T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 170902, "given_name": "Maria Chiara", "family_name": "Buscarinu", "ORCID": "http://orcid.org/0000-0002-4839-1528", "country": null }, { "author_id": 311918, "given_name": "Benedetta", "family_name": "Cerasoli", "ORCID": null, "country": null }, { "author_id": 274410, "given_name": "Viviana", "family_name": "Annibali", "ORCID": null, "country": null }, { "author_id": 311919, "given_name": "Claudia", "family_name": "Policano", "ORCID": null, "country": null }, { "author_id": 271970, "given_name": "Luana", "family_name": "Lionetto", "ORCID": null, "country": null }, { "author_id": 271971, "given_name": "Matilde", "family_name": "Capi", "ORCID": null, "country": null }, { "author_id": 170900, "given_name": "Rosella", "family_name": "Mechelli", "ORCID": "http://orcid.org/0000-0001-5842-3100", "country": null }, { "author_id": 148216, "given_name": "Silvia", "family_name": "Romano", "ORCID": "http://orcid.org/0000-0003-0499-8843", "country": "IT" }, { "author_id": 271972, "given_name": "Arianna", "family_name": "Fornasiero", "ORCID": null, "country": null }, { "author_id": 311920, "given_name": "Gianluca", "family_name": "Mattei", "ORCID": null, "country": null }, { "author_id": 306330, "given_name": "Eleonora", "family_name": "Piras", "ORCID": null, "country": null }, { "author_id": 311921, "given_name": "Daniela Francesca", "family_name": "Angelini", "ORCID": null, "country": null }, { "author_id": 243787, "given_name": "Luca", "family_name": "Battistini", "ORCID": null, "country": null }, { "author_id": 247807, "given_name": "Maurizio", "family_name": "Simmaco", "ORCID": null, "country": null }, { "author_id": 293104, "given_name": "Renato", "family_name": "Umeton", "ORCID": null, "country": null }, { "author_id": 170907, "given_name": "Marco", "family_name": "Salvetti", "ORCID": "http://orcid.org/0000-0002-0501-8803", "country": null }, { "author_id": 207534, "given_name": "Giovanni", "family_name": "Ristori", "ORCID": "http://orcid.org/0000-0002-6598-6777", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Altered intestinal permeability", "patients", "multiple sclerosis", "A pilot study" ], "doi": "10.1177/1352458516652498", "access": "restricted", "takeaways": " Alterations of intestinal permeability (IP) may contribute to the pathophysiology of immune-mediated diseases . Measurement of lactulose (L) and mannitol (M) levels in urine samples allowed to quantify gut dysfunction . The proportion of participants with increased IP was significantly higher in patients than in HDs .", "categories": [] }, { "article_id": 382061, "title": "Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To report on ten Caucasian patients with NMO spectrum disorders (NMOSD) and MG and to provide a comprehensive review of the literature. </jats:p></jats:sec><jats:sec><jats:title>Method:</jats:title><jats:p> Retrospective study. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In total, 26 patients (m:f = 1:12; Caucasian in 12) with MG (generalized in 17) and NMOSD (NMO in 21, longitudinally extensive transverse myelitis in five) were identified from the authors’ own files ( n = 10) and the previous literature ( n = 16). MG preceded NMOSD in 24/25 cases (96%). AQP4-Ab were tested in 20 patients and were positive in 17 (85%). Twenty out of 25 patients (80%) had been treated with thymectomy or thymic irradiation, which preceded NMOSD in all cases (median latency, 12 years; range, 0.3–32). At last follow-up, complete remission of MG was reported in 15/22 (68%), and MG was well controlled with pyridostigmine in three. Co-existing autoimmune disorders or autoimmune antibodies were reported in 17 patients. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Our study demonstrates that i) AQP4-Ab-positive NMOSD are more commonly associated with MG in Caucasians than previously thought; ii) MG precedes NMOSD in most cases, often by more than a decade; iii) NMOSD almost exclusively occur in females with juvenile or early-onset MG; and iv) MG frequently takes an unusually mild course in patients with NMOSD. A history of thymectomy could be a possible risk factor for the later development of NMOSD. We recommend testing for AQP4-Ab in MG patients presenting with atypical motor or optic symptoms. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512440349", "published_date": "2011-12-19T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 254663, "given_name": "S", "family_name": "Jarius", "ORCID": null, "country": null }, { "author_id": 254858, "given_name": "F", "family_name": "Paul", "ORCID": null, "country": null }, { "author_id": 251581, "given_name": "D", "family_name": "Franciotta", "ORCID": null, "country": null }, { "author_id": 267331, "given_name": "J", "family_name": "de Seze", "ORCID": null, "country": null }, { "author_id": 309823, "given_name": "C", "family_name": "Münch", "ORCID": null, "country": null }, { "author_id": 278636, "given_name": "M", "family_name": "Salvetti", "ORCID": null, "country": null }, { "author_id": 254849, "given_name": "K", "family_name": "Ruprecht", "ORCID": null, "country": null }, { "author_id": 309824, "given_name": "M", "family_name": "Liebetrau", "ORCID": null, "country": null }, { "author_id": 270074, "given_name": "KP", "family_name": "Wandinger", "ORCID": null, "country": null }, { "author_id": 244925, "given_name": "G", "family_name": "Akman-Demir", "ORCID": null, "country": null }, { "author_id": 309825, "given_name": "A", "family_name": "Melms", "ORCID": null, "country": null }, { "author_id": 309826, "given_name": "W", "family_name": "Kristoferitsch", "ORCID": null, "country": null }, { "author_id": 254664, "given_name": "B", "family_name": "Wildemann", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Neuromyelitis optica spectrum disorders", "patients", "myasthenia gravis", "ten new aquaporin-4 antibody positive cases", "a review", "the literature" ], "doi": "10.1177/1352458511431728", "access": "restricted", "takeaways": " Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders . MG preceded NMOSD in 24/25 cases (96%) of 26 patients with MG and NMO spectrum disorders (NMOSD) and MG . AQP4-Ab were tested in 20 patients and were positive in 17 (85%) of those with MG .", "categories": [] }, { "article_id": 381431, "title": "Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Cerebrospinal fluid (CSF) is in contact with brain parenchyma and ventricles, and its composition might influence the cellular physiology of oligodendrocyte progenitor cells (OPCs) thereby contributing to multiple sclerosis (MS) disease pathogenesis. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To identify the transcriptional changes that distinguish the transcriptional response induced in proliferating rat OPCs upon exposure to CSF from primary progressive multiple sclerosis (PPMS) or relapsing remitting multiple sclerosis (RRMS) patients and other neurological controls. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We performed gene microarray analysis of OPCs exposed to CSF from neurological controls, or definitive RRMS or PPMS disease course. Results were confirmed by quantitative reverse transcriptase polymerase chain reaction, immunocytochemistry and western blot of cultured cells, and validated in human brain specimens. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We identified common and unique oligodendrocyte genes for each treatment group. Exposure to CSF from PPMS uniquely induced branching of cultured progenitors and related transcriptional changes, including upregulation ( P<0.05) of the adhesion molecule GALECTIN-3/ Lgals3, which was also detected at the protein level in brain specimens from PPMS patients. This pattern of gene expression was distinct from the transcriptional programme of oligodendrocyte differentiation during development. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Despite evidence of morphological differentiation induced by exposure to CSF of PPMS patients, the overall transcriptional response elicited in cultured OPCs was consistent with the activation of an aberrant transcriptional programme. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458515573094", "published_date": "2015-05-06T00:00:00Z", "sources": [ "SAGE Publications" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 279956, "given_name": "Jeffery D", "family_name": "Haines", "ORCID": null, "country": null }, { "author_id": 279957, "given_name": "Oscar G", "family_name": "Vidaurre", "ORCID": null, "country": null }, { "author_id": 253289, "given_name": "Fan", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 279958, "given_name": "Ángela L", "family_name": "Riffo-Campos", "ORCID": null, "country": null }, { "author_id": 279959, "given_name": "Josefa", "family_name": "Castillo", "ORCID": null, "country": null }, { "author_id": 208661, "given_name": "Bonaventura", "family_name": "Casanova", "ORCID": "http://orcid.org/0000-0003-3806-925X", "country": null }, { "author_id": 209454, "given_name": "Patrizia", "family_name": "Casaccia", "ORCID": "http://orcid.org/0000-0002-4785-9264", "country": null }, { "author_id": 170152, "given_name": "Gerardo", "family_name": "Lopez-Rodas", "ORCID": "http://orcid.org/0000-0001-8367-653X", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Multiple sclerosis patient-derived CSF", "transcriptional changes", "oligodendrocyte progenitors" ], "doi": "10.1177/1352458515573094", "access": "open", "takeaways": " Cerebrospinal fluid (CSF) is in contact with brain parenchyma and ventricles, and its composition might influence the cellular physiology of oligodendrocyte progenitor cells . Exposure to CSF from PPMS uniquely induced branching of cultured progenitors and related transcriptional changes, including upregulation of the adhesion molecule GALECTIN-3/ Lgals3 . This pattern of gene expression was distinct from the transcriptional programme of", "categories": [] } ] }